It is given as a subcutaneous injection, typically once weekly, using a dose-escalation approach to improve tolerability
Additionally, carnitine has shown protective properties against hypertension, hyperlipidemia, hyperglycemia, diabetic ketoacidosis, insulin resistance, insulin-dependent diabetes mellitus, obesity, and other conditions that enhance cardiovascular pathology
The Insurance Maze: Can It Cover Your GLP-1
Exceptional Selectivity Stimulates GH release without significantly affecting cortisol, prolactin, or ACTH the defining advantage over older GHRPs like GHRP-6 and GHRP-2
This significant weight loss drastically minimizes risks for adverse health outcomes, including cardiovascular problems, stroke, and Type 2 Diabetes
Other GLP-1 receptor agonists may be considered, though they share a similar side effect profile